An evaluation of talimogene laherparepvec for the treatment of melanoma

References

• United States Food and Drug Administration. Imlygic. (October 11, 2019).
   Google Scholar
• European Medicines Agency. European public assessment report for imlygic. (October 11,2019).
   Google Scholar
• Therapeutic Goods Administration. Australian public assessment report for imlygic. (October 11, 2019).
   Google Scholar
• Rehman H, Silk AW, Kane MP, et al. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.
   PubMed Web of Science ®Google Scholar
• Raman SS, Hecht JR, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019;11(8):705–723.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.
   PubMed Web of Science ®Google Scholar
• Amgen. Study protocol: a phase 2, multicenter, open-label, single-arm trial to evaluate the correlation between objective response rate and baseline intratumoral CD8+ cell density in subjects with unresected stage IIIB to IVM1c melanoma treated with talimogene laherparapvec. NCT 02366195
   Google Scholar
• Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–6747.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–5771.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Amatruda T, Reid T, et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016;4:12.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, Deraffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718–730.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM Phase III clinical trial. Ann Surg Oncol. 2016;23(13):4169–4177.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio F, Harrington KJ, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Mehnert M, Nemunaitis J, et al. Biodistribution and shedding of talimogene laherparepvec (T-VEC) in patients with unresectable stage IIIB/IV melanoma. Society for Melanoma Research (October 2017).
   Google Scholar
• Andtbacka RHI, Amatruda T, Nemunaitis J, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 2019;47:89–97.
   PubMed Web of Science ®Google Scholar
• Perez MC, Miura JT, Naqvi SMH, et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. Ann Surg Oncol. 2018;25(13):3960–3965.
   PubMed Web of Science ®Google Scholar
• Mohr P, Haferkamp S, Pinter A, et al. Real-world use of talimogene laherparepvec in german patients with stage IIIB to IVM1a melanoma: a retrospective chart review and physician survey. Adv Ther. 2019;36(1):101–117.
   PubMed Web of Science ®Google Scholar
• Louie RJ, Perez MC, Jajja MR, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg. 2019;228(4):644–649.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Dummer R, Gyorki DE, et al. Interim analysis of a randomized, open-label phase 2 study of talimogene lagerparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery for resectable stage IIIB-IVM1a melanoma. Society of Surgical Oncology (March 2019).
   Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119 e1110.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e551.
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–1667.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Long G, Dummer R, Ribas A, et al. EFficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:9568.
   Web of Science ®Google Scholar
• Aris M, Barrio MM. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol. 2015;6:46.
   PubMed Web of Science ®Google Scholar